Thought what others were doing was of interest also.
P538 Long-Term Open Label Treatment of Psoriatic Arthritis with Infliximab
Christian Antoni; Friedrich-Alexander-University, 91056 Erlangen, Germany; M Grunke;
Friedrich-Alexander-University, Erlangen, Germany; C Dechant;
Friedrich-Alexander-University, Erlangen, Germany; J Kalden; Friedrich-Alexander-University,
Erlangen, Germany
P539 Infliximab Monotherapy Normalizes Keratinocyte Differentiation and Decreases
Inflammation in Skin Biopsies from Patients with Moderate to Severe Plaque Psoriasis
Alice B Gottlieb, MD, PhD; UMDNJ-Robert Wood Johnson Medical Center, New Brunswick,
NJ; S Mahud; UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, NJ; R
Ramamurthi; UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, NJ; Pat
Romano, RN; UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, NJ
P540 Infliximab Prevents Relapse of Moderate to Severe Psoriasis in Responding
Patients
Alice B Gottlieb, MD, PhD; UMDNJ-Robert Wood Johnson Medical School, New Brunswick,
NJ; Pat Romano, RN; UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ;
Umesh Chaudhari, MD; UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ;
Daniel Baker, MD; Centocor Inc, Malvern, PA
P545 Successful Treatment of Pediatric Psoriasis with Infliximab
M Alan Menter, MD; Baylor University Medical Center, Dallas, TX; Sarah Jerome, PhD;
Centocor, Inc, Malvern, PA; John J Cush, MD; Medical Director, Arthritis Consultation Center,
Presbyterian Hospital of Dallas, Dallas, TX
P546 Efalizumab (anti-CD11a) Induction and Maintenance Treatment During a 12-Month
Trial in Patients with Moderate to Severe Plaque Psoriasis: Preliminary Findings
Alice Gottlieb, MD; University of Medicine & Dentistry of NJ & Robert Wood Johnson Medical
School, New Brunswick, NJ
P547 Pharmacodynamic Effects of Subcutaneous (SC) Administration of Efalizumab
(anti-CD11a)
Wolfgang Dummer, MD; Genentech, Inc, South San Francisco, CA
P548 Efalizumab (anti-CD11a) is Safe and Well Tolerated in the Treatment of Moderate to
Severe Plaque Psoriasis: Pooled Results of Two Phase III Clinical Trials
John Y Koo, MD; UCSF Psoriasis and Skin Treatment Center, San Francisco, CA
P549 Time to Onset of Improvement During Efalizumab (anti-CD11a) Therapy in Patients
with Moderate to Severe Plaque Psoriasis
Alan Menter, MD; Psoriasis Research Center, Dallas, TX
York, NY; Richard Scher, MD; New
York University, New York, NY; Ken Washenik, MD; New York University, New York, NY;
Patients with Psoriatic Arthritis:
Results of a Phase 3 Multicenter Clinical Trial
Mark Lebwohl, MD; Mount Sinai School of Medicine, New York, NY; Alice Gottlieb, MD, PhD;
UMDNJ-RWJMS, New Brunswick, NJ; Philip Mease, MD; Seattle Rheumatology Associates,
Seattle, WA; Daniel Burge, MD; Immunex Corp; for the Enbrel Psoriatic Arthritis Study Group,
Seattle, WA
P566 Infliximab in the Treatment of Psoriasis and Psoriatic Arthritis
Roy M Fleishmann, MD; University of Texas, Southwestern Medical Center at Dallas, Dallas,
TX; Michael Stevens, MD; UCSF, International Rheumatology Network, NCRA, San Mateo,
CA; Marketa Limova, MD; UCSF, San Francisco, CA; Elliot Rosenstein, MD; Arthritis and
Rheumatic Disease Center, St Baranabas Medical Center, Livingston, NJ
P567 Case Report: Generalized Pustular Psoriasis Treated with Anti-TNF (Infliximab)
Therapy
Boni E Elewski, MD; University of Alabama at Birmingham, Birmingham, AL
P568 The Combination of Infliximab and Methotrexate for Severe Recalcitrant Psoriasis
Brian G Kirby, MD; University of Manchester, Manchester, England; Christopher Griffiths, MD;
University of Manchester, Manchester, England
P573 Continued Treatment with Efalizumab (anti-CDIIa) Improves Outcome in Patients
with Moderate to Severe Plaque Psoriasis
Mark Lebwohl, MD; Mt Sinai School of Medicine, New York, NY
P574 Alefacept Selectively Reduces Memory-Effector (CD45RO+) T Cells: A Mechanism
for Impoving Clinical Symptoms of Psoriasis without Impairing Immune Function
Kenneth B Gordon, MD; Northwestern University, Clinical Trials Unit, Chicago, IL; Akshay
Vaishnaw, MD, PhD; Biogen, Inc, Cambridge, MA; Kevin Cooper; University Hospitals Health
Systems, Cleveland, OH
P576 Subcutaneous Efalizumab (anti-CDIIa) is Effective in the Treatment of Moderate to
Severe Plaque Psoriasis: Pooled Results of Two Phase III Cinical Trials
Alice Gottlieb, MD; University of Medicine& Dentistry of NJ/Robert Wood Johnson Med
School, New Brunswick, NJ
P577 Immune Response to Neo-or Recall Antigens is Not Altered by Alefacept
Alice B Gottlieb, MD, PhD; University of Medicine and Dentistry of NJ, New Brunswick, NJ;
Akshay Vaishnaw, MD, PhD; Biogen, Inc, Cambridge, MA; Kenneth Gordon, MD;
Northwestern University, Chicago, IL
P578 Health-Related Quality of Life Impact of Weekly Intravenous or Intramuscular
Alefacept in Patients with Psoriasis: Results from Two Randomized, Placebo-Controlled
Phase III Trials
Alan Menter, MD; Texas Dermatology Associates, Dallas, TX; Alice Gottlieb, MD, PhD;
University of Medicine and Dentistry of NJ, New Brunswick, NJ; Christopher Griffiths; Hope
Hospital, Salford, UK; Margaret Mordin, MS; Covance Health Economics and Outcomes
Service, Inc, Gaithersburg, MD
P579 Results of Repeat Courses of Alefacept Therapy for the Treatment of Chronic
Plague Psoriasis
Nick Lowe, MD; Clinical Research Specialists, Santa Monica, CA; Gerald Krueger, MD;
University of Utah Health Sciences Center, Salt Lake City, UT; Alan Menter, MD; Texas
Dermatology Associates, Dallas, TX; Charles Ellis, MD; University of Michigan Medical School,
Ann Arbor, MI
P580 Results of a Multiple-Course, Randomized, Phase III Study of Alefacept (Human
LFA-3/IgG1) in Patients with Chronic Plague Psoriasis
Mark Lebwohl, MD; The Mount Sinai School of Medicine, New York, NY; Gloria Vigliani, MD;
Biogen, Inc, Cambridge, MA; Gerald Krueger, MD; University of Utah Health Sciences
Center, Salt Lake City, UT
P581 Intramuscular Administration of Alefacept is Safe and Effective in Patients with
Chronic Plague Psoriasis: Results of an International Randomized, Double-Blind,
Placebo-Controlled, Dose-Comparison Phase III Study
Enno Christophers, MD; Klinikum an der Universitaet Kiel, Kiel, Germany; Elena Rizova, MD,
PhD; Biogen, Inc, Nanterre Cedax Paris, France; Mark Lebwohl, MD; The Mount Sinai
School of Medicine, New York, NY
P582 Alefacept Reduces Synovial Inflammatory Infiltrate and Improves Outcome in
Psoriasis Arthritis
Amber Y Goedkoop, MD; Academic Medical Centre, Amsterdam, Netherlands; Huibert
Dinant, MD; Academic Medical Centre, Amsterdam, Netherlands; Arno Van Kuijk; VU
Academic Hopital, Amsterdam, Netherlands; Menno de Rie, MD; Academic Medical Centre,
Amsterdam, Netherlands
P583 Alefacept (Human LFA-3/IgG1) is Well Tolerated and Non-Immunogenic: Results of
Two Randomized, Placebo-Controlled Phase III Trials
Gerald Krueger, MD; University of Utah, Health Sciences Center, Dept of Dermatology, Salt
Lake City, UT; Akshay Vaishnaw, MD, PhD; Biogen, Inc, Cambridge, MA; Kenneth Gordon,
MD; Northwestern University, Clinical Trials Unit, Chicago, IL
P584 Duration of Response to Alefacept Therapy in Patients with Chronic Plague
Psoriasis
Gerald Krueger, MD; University of Utah, Health Sciences Center, Dept of Dermatology, Salt
Lake City, UT; Elena Rizova, MD, PhD; Biogen, Inc, Nanterre Cedax, France
P585 Continuous Treatment Improves Outcomes in Patients with Moderate to Severe
Plaque Psoriasis Treated with Efalizumab (Anti-Colla)
Kenneth B Gordon, MD; Northwestern University, Chicago, IL
P586 Efalizumab (Anti-Colla): Promising Results When Used for the Treatment of
Moderate to Severe Plaque Psoriasis
Craig Leornadi, MD; Radiant Research, Inc, St Louis, MO
P587 Efalizumab (Anti-Colla) Improves Quality of Life in Patients with Moderate to
Severe Plaque Psoriasis
Steven R Feldman, MD; Wake Forest University School of Medicine, Winston-Salem, NC
P588 Patient Response to Efalizumab (Anti-Colla) Therapy Maintained with
Semi-Monthly Dosing
David Pariser, MD; Virginia Clinical Research, Norfolk, VA
P590 Study Design and Demographics of Two Phase III Trials to Evaluate Weekly
Intravenous and Intramuscular Administration of Alefacept in Chronic Plaque Psoriasis
Richard D Langley, MD, FRCP; Queen Elizabeth II Health Sciences Center, Halifax, Nova
Scocia; Gloria Vigliani, MD; Biogen, Inc, Cambridge, MA; Mark Lebwohl, MD; The Mount
Sinai School of Medicine, New York, NY
© American Academy of Dermatology, 2000. All rights reserved.
Produced by NetOn-Line Services. |
